BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 28504252)

  • 1. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.
    Mangal S; Gao W; Li T; Zhou QT
    Acta Pharmacol Sin; 2017 Jun; 38(6):782-797. PubMed ID: 28504252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.
    Yu XY; Jin X; Shou ZX
    Drug Deliv; 2021 Dec; 28(1):1995-2010. PubMed ID: 34569401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
    Islam N; Richard D
    Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
    Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
    Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhaled chemotherapy - Part 1: General concept and current technological challenges].
    Rosière R; Hureaux J; Levet V; Amighi K; Wauthoz N
    Rev Mal Respir; 2018 Apr; 35(4):357-377. PubMed ID: 29731372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled chemotherapy in lung cancer: future concept of nanomedicine.
    Zarogoulidis P; Chatzaki E; Porpodis K; Domvri K; Hohenforst-Schmidt W; Goldberg EP; Karamanos N; Zarogoulidis K
    Int J Nanomedicine; 2012; 7():1551-72. PubMed ID: 22619512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
    Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
    J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.
    Mundra V; Peng Y; Kumar V; Li W; Miller DD; Mahato RI
    Drug Deliv Transl Res; 2015 Jun; 5(3):199-208. PubMed ID: 25924699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loco-regional administration of nanomedicines for the treatment of lung cancer.
    Garrastazu Pereira G; Lawson AJ; Buttini F; Sonvico F
    Drug Deliv; 2016 Oct; 23(8):2881-2896. PubMed ID: 26585837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.
    Rudokas M; Najlah M; Alhnan MA; Elhissi A
    Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):60-72. PubMed ID: 26938856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model.
    Karra N; Nassar T; Laenger F; Benita S; Borlak J
    Curr Cancer Drug Targets; 2013 Jan; 13(1):11-29. PubMed ID: 23030233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol Delivery in the Treatment of Lung Cancer.
    Storti C; Le Noci V; Sommariva M; Tagliabue E; Balsari A; Sfondrini L
    Curr Cancer Drug Targets; 2015; 15(7):604-12. PubMed ID: 26033086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine for Treatment of Lung Cancer.
    Hussain S
    Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized chemotherapy.
    Gagnadoux F; Hureaux J; Vecellio L; Urban T; Le Pape A; Valo I; Montharu J; Leblond V; Boisdron-Celle M; Lerondel S; Majoral C; Diot P; Racineux JL; Lemarie E
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):61-70. PubMed ID: 18518832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
    Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy.
    Kumar M; Jha A; Dr M; Mishra B
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1459-1472. PubMed ID: 32684002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.